FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Go back to FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.| Abbott Laboratories (NYSE: ABT) | Delayed: 105.77 -2.56 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.33 | 52 Week High | $46.38 | |||
| Open | $108.36 | 52 Week Low | $36.00 | |||
| Day High | $108.39 | P/E | 70.51 | |||
| Day Low | $105.24 | EPS | $1.50 | |||
| Volume | 6,987,506 | |||||
| (NASDAQ: FRNM) | Delayed: 15.99 -0.32 (1.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.31 | 52 Week High | $ | |||
| Open | $16.74 | 52 Week Low | $ | |||
| Day High | $16.74 | P/E | N/A | |||
| Day Low | $15.79 | EPS | $ | |||
| Volume | 390,091 | |||||
